Nasdaq

Perspective Therapeutics Announces Acceptance of Key Radiopharmaceutical Data for Presentation at ASCO 2025 Annual Meeting

Perspective Therapeutics announced data presentations at ASCO 2025 for its cancer treatment programs [212Pb]VMT-α-NET and [212Pb]VMT01. Perspective Therapeutics, Inc. announced that it will present ...
Nasdaq

Perspective Therapeutics, Inc. Announces Clinical Updates and Recruitment Progress for Novel Radiopharmaceuticals Ahead of 2025 ASCO Meeting

Perspective Therapeutics, Inc. provided a business update highlighting progress in its clinical trials and manufacturing capabilities as of May 2025. The company is actively enrolling patients in ...